Cilta-Cel
High Risk Smoldering Multiple Myeloma
PETHEMA FoundationCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the High Risk Smoldering Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Regeneron Pharmaceuticals | Phase 3 | BB |
FILGRASTIM Regeneron Pharmaceuticals | Phase 3 | BB |
Linvoseltamab Regeneron Pharmaceuticals | Phase 3 | BB |
cc-5013 Irene Ghobrial, MD | Phase 3 | BB |
DARATUMUMAB Regeneron Pharmaceuticals | Phase 3 | BB |
View all 48 →
Same molecule, other indications
Cilta-Cel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →